These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 28984786)
21. Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors. Zhou B; Fang B; Yan S; Wang W Clin Lab; 2017 Jul; 63(7):1251-1259. PubMed ID: 28792692 [TBL] [Abstract][Full Text] [Related]
22. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours. Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069 [TBL] [Abstract][Full Text] [Related]
24. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series. Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939 [TBL] [Abstract][Full Text] [Related]
25. Elevated Ki-67 labeling index in 'synchronous liver metastases' of well differentiated enteropancreatic neuroendocrine tumor. Zen Y; Heaton N Pathol Int; 2013 Nov; 63(11):532-8. PubMed ID: 24274715 [TBL] [Abstract][Full Text] [Related]
26. The Influence of Tumor Stage on the Prognostic Value of Ki-67 Index and Mitotic Count in Small Intestinal Neuroendocrine Tumors. Sun Y; Lohse C; Smyrk T; Hobday T; Kroneman T; Zhang L Am J Surg Pathol; 2018 Feb; 42(2):247-255. PubMed ID: 29016403 [TBL] [Abstract][Full Text] [Related]
27. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Shi C; Gonzalez RS; Zhao Z; Koyama T; Cornish TC; Hande KR; Walker R; Sandler M; Berlin J; Liu EH Am J Clin Pathol; 2015 Mar; 143(3):398-404. PubMed ID: 25696798 [TBL] [Abstract][Full Text] [Related]
28. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate. McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170 [TBL] [Abstract][Full Text] [Related]
29. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225 [TBL] [Abstract][Full Text] [Related]
30. Comparison of Three Ki-67 Index Quantification Methods and Clinical Significance in Pancreatic Neuroendocrine Tumors. Kroneman TN; Voss JS; Lohse CM; Wu TT; Smyrk TC; Zhang L Endocr Pathol; 2015 Sep; 26(3):255-62. PubMed ID: 26072124 [TBL] [Abstract][Full Text] [Related]
31. Ki-67 Index of 5% is Better Than 2% in Stratifying G1 and G2 of the World Health Organization Grading System in Pancreatic Neuroendocrine Tumors. Gao SW; Huang CS; Huang XT; Chen LH; Chen W; Cai JP; Yin XY Pancreas; 2019 Jul; 48(6):795-798. PubMed ID: 31210659 [TBL] [Abstract][Full Text] [Related]
32. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis. Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460 [TBL] [Abstract][Full Text] [Related]
33. The diagnostic value of FNA biopsy in grading pancreatic neuroendocrine tumors. Laskiewicz L; Jamshed S; Gong Y; Ainechi S; LaFemina J; Wang X Cancer Cytopathol; 2018 Mar; 126(3):170-178. PubMed ID: 29266776 [TBL] [Abstract][Full Text] [Related]
34. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms. Sigel CS; Guo H; Sigel KM; Zhang M; Rekhtman N; Lin O; Klimstra DS; Jungbluth AA; Tang LK Cancer Cytopathol; 2017 Mar; 125(3):188-196. PubMed ID: 28094897 [TBL] [Abstract][Full Text] [Related]
36. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636 [TBL] [Abstract][Full Text] [Related]
37. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors. Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489 [TBL] [Abstract][Full Text] [Related]
38. Correlation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours. Barnes J; Johnson SJ; French JJ Ann R Coll Surg Engl; 2017 Mar; 99(3):193-197. PubMed ID: 27490982 [TBL] [Abstract][Full Text] [Related]
39. Insulinoma-associated protein 1 (INSM1) is a robust marker for identifying and grading pancreatic neuroendocrine tumors. Kim D; Viswanathan K; Goyal A; Rao R Cancer Cytopathol; 2020 Apr; 128(4):269-277. PubMed ID: 31977134 [TBL] [Abstract][Full Text] [Related]
40. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Remes SM; Tuominen VJ; Helin H; Isola J; Arola J Am J Surg Pathol; 2012 Sep; 36(9):1359-63. PubMed ID: 22895268 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]